RxDoctor Payments Data

Danica May, MD

Urology · Kansas City, KSNPI 1386061760

Payments from drug & device makers

$916in general payments, 2019–2025

Across 20 payments — averaging $45.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$403
  • Johnson & Johnson$162
  • Astellas Pharma US Inc$111
  • Ambu Inc.$90
  • Rochester Medical Corporation$43
  • Hollister Incorporated$35
  • plus $72 from 4 others

What the payments were for

  • Food & beverage$916100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boston Scientific6$403
Johnson & Johnson2$162
Astellas Pharma US Inc2$111
Ambu Inc.3$90
Rochester Medical Corporation1$43
Hollister Incorporated2$35
Biotissue Holdings Inc.1$21
Profound Medical Corp.1$20
Sumitomo Pharma America, Inc.1$18
Coloplast1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$916 in reported general payments places this provider in the 30th percentile of 111 urology providers in Kansas.

See all urology providers in Kansas

Medicare billing

Part B allowed, 2024
$100,376
Medicare patients
354
Services billed
885

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron56$33,758
GemtesaVibegron14$7,817
Trospium Chloride ErTrospium Chloride31$4,080
Tamsulosin Hcl172$2,542
Oxybutynin Chloride ErOxybutynin Chloride64$2,206
Solifenacin Succinate29$1,522
Finasteride76$1,039
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst21$696
Ciprofloxacin Hcl50$135
Cephalexin18$110
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim14$44

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$111$33,75856 claims
Sumitomo Pharma America, Inc.Gemtesa$18$7,81714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 111 urology providers in Kansas.

Other urology in Kansas City

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →